Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 28, 2005

View Archived Issues

Enrollment under way in phase IV study of Modrenal

Lomucin studied in phase II trial for cystic fibrosis

Recombinant vaccine induces an immune response in mice challenged with H9N2 influenza

CHF-3381 demonstrates in vivo efficacy for pain associated with central sensitization

BioLineRx receives funding to support development of BL-1020 and others

U.S. phase III study begins for Miraxion in Huntington's disease

Anticancer activity observed for Welichem Biotech's WBI-2000 series

CollaGenex studies incyclinide for acne

Amrad seeks to change name to Zenyth Therapeutics

Scios to study nesiritide in acute decompensated heart failure

CH-1504 for rheumatoid arthritis studied in phase I trials

Enrollment discontinued in Avastin phase II study in ovarian cancer

ABHS shows synergy with tPA in a preclinical model of acute ischemic stroke

Corgentech and AlgoRx to merge

Recent patents disclose novel analgesic agents

Rozerem now available

New therapeutic agents for gastrointestinal disorders revealed

AstraZeneca submits NDA for Symbicort

European orphan drug status for Troxatyl in AML

Antiasthmatic actions of L-97-1 in preclinical tests

Novel peptide from shark liver exerts antidiabetic effects in mice

A novel glucokinase activator shows promise as an antidiabetic

Lipitor approved to reduce risk of strokes and heart attacks in diabetics

Antidiabetic effect of A2B adenosine receptor antagonism

New data indicate superior potency of MB-06322 as a treatment for type 2 diabetes

PPARalpha/gamma agonist improves glucose tolerance without stimulating weight gain and adiposity

Recent Sumitomo patent covers novel treatments for anxiety and depression

Supplemental BLA submitted for Tysabri for MS

Janssen patents novel antimycobacterial agents

Update on AAE-581 in the management of osteoporosis

New data supports the use of exenatide in the treatment of type 2 diabetes

Dacarbazine plus natural IFN alpha improves survival in patients with high-risk cutaneous melanoma